About

Dr. Sharon Shacham has served on Acrivon's Board since October 2020. She has served as CEO of Regenimo Biosciences since September 2025 and co-founded and is Managing Director of the venture-capital firm E44 Ventures. She founded Karyopharm Therapeutics in 2008 and served in roles including Chief Scientific Officer and President, leading the scientific and clinical work behind selinexor (Xpovio), a first-in-class oral XPO1 inhibitor. Earlier she was Senior Vice President of Drug Development at Epix Pharmaceuticals. She currently serves as a director of Nasus Pharma. Dr. Shacham holds a B.S. in chemistry, a Ph.D. in biophysical chemistry and an M.B.A. from Tel Aviv University. She serves on Acrivon's Compensation Committee.

Roles

Acrivon Therapeutics, Inc.
Director · Current role
October 2020–present
Regenimo Biosciences
Chief Executive Officer
September 2025 - present
E44 Ventures
Co-Founder & Managing Director
2022 - present
Karyopharm Therapeutics Inc.
Founder; Chief Scientific Officer / President
2008 - 2022
Epix Pharmaceuticals
Senior Vice President, Drug Development
—

External Roles

Nasus Pharma, Ltd.
Director
—

Director Compensation

FY 2025
Fees earned or paid in cash
$47,500
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$17,870
ComponentStock options granted during 2025, ASC 718 grant-date fair value
Total
$65,370

Also at Acrivon Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.